NL-OMON49772已完成不适用
Intratumoral holmium microspheres brachytherapy for patients with pancreatic cancer; a single center, non-randomized, feasibility study in an open surgical setting- the SLOTH1 study - SLOTH-1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •1. Female or male aged 18 years and over.
- •2. Diagnosis of primary borderline resectable pancreatic cancer by Dutch
- •Pancreatic Cancer Group (DPCG) guidelines:
- •3. Patient is deemed eligible for surgical resection of the pancreatic cancer,
- •however, during open surgery a more advanced disease than initially anticipated
- •is found and resection is no longer feasible.
- •4. Life expectancy of 12 weeks or longer.
- •5. World Health Organisation (WHO) Performance status 0-1.
- •6. One or more measurable lesions of at least 10 mm in the longest diameter by
- •spiral CT or MRI according to the Response Evaluation Criteria in Solid Tumours
- •(RECIST) 1.1 criteria.
- •7. Negative pregnancy test for women of childbearing potential.
排除标准
- •1. Radiation therapy within the last 4 weeks before the start of study therapy.
- •2. Calcifications in the pancreas or tumour that are highly expected to
- •obstruct the needle tract
- •3. Any unresolved toxicity greater than National Cancer Institute (NCI), Common
- •Terminology Criteria for Adverse Events (CTCAE version 4.0) grade 2 from
- •previous anti-cancer therapy.
- •4. Serum bilirubin > 250 µmol/l
- •5. Leukocytes < 4.0 10^9/l and/or platelet count < 100 10^9/l.
- •6. Significant cardiac event (e.g. myocardial infarction, superior vena cava
- •(SVC) syndrome, New York Heart Association (NYHA) classification of heart
- •disease >=2 within 3 months before entry, or presence of cardiac disease that in
- •the opinion of the Investigator increases the risk of ventricular arrhythmia.
- •7. Patient is deemed ineligible for implantation of 166Ho by an expert panel
- •(surgeon, nuclear medicine physician and researcher) due to tumour anatomy or
- •nearby structures.
- •8. Pregnancy or breast feeding (women of child-bearing potential).
- •9. Patients suffering from psychic disorders that make a comprehensive
- •judgement impossible, such as psychosis, hallucinations and/or depression.
- •10. Patients who are declared incompetent.
研究者
相似试验
招募中
不适用
Percutaneous intratumoural holmium microspheres brachytherapy for patients with pancreatic cancer; a single centre, prospective safety and feasibility studyPancreatic cancerpancreatic adenocarcinoma100179901001471310017998NL-OMON51321Radboud Universitair Medisch Centrum6
已完成
2 期
Radioactive holmium microspheres for the treatment of patients with unresectable liver metastases; a single center, interventional, non-randomized, phase II efficacy (HEPAR II) trial.NL-OMON39704niversitair Medisch Centrum Utrecht48
已完成
不适用
Radioactive holmium microspheres for the treatment of patients with non-resectable liver metastases of mixed origin; a single center, interventional, non-randomized, open label, safety study.liver metastases of mixed origines10019815NL-OMON35649niversitair Medisch Centrum Utrecht24
已完成
不适用
Radioembolization with holmium-containing microspheres: Use of the Holmium Platform for the treatment of patients with hepatocellular carcinomaC22.0Liver cell carcinomaDRKS00032073niversitätsklinikum Jena, Klinik für Nuklearmedizin27
已完成
不适用
Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic CancerPancreas CancerNCT05191498Radboud University Medical Center3
